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Disease activityAbstract Aim of the work: This study was designed to measure the serum level of matrix
metalloproteinase-3 (MMP-3) in rheumatoid arthritis (RA) patients and its correlation with func-
tional status, disease activity and joint damage.
Patients and methods: The study included 50 RA patients satisfying 2010 ACR/EULAR classi-
fication criteria recruited from Bani-Suef University Hospital and 20 controls. Functional disability
was assessed according to Modified Health Assessment Questionnaire (MHAQ). Disease activity
score in 28-joints (DAS28) and visual analogue scale (VAS) of pain were evaluated. Radiological
joint damage was assessed by Van der Heijde-modified Sharp Score (vdHSS). Serum levels of
MMP-3 were measured for all subjects.
Results: RA patients (44 females and 6 males) had a mean age of 46.36 ± 13.63 years and dis-
ease duration of 5.6 ± 4.75 years. Serum MMP-3 levels were higher in patients than in controls
(46.78 ± 46.99 versus 1.98 ± 1.71 ng/ml respectively, p= 0.0001) and significantly correlated with
erythrocyte sedimentation rate (p= 0.001) and were significantly higher in patients with positive C-
reactive protein, rheumatoid factor and anti-cyclic citrullinated peptide (p= 0.0001, p= 0.009,
p= 0.042, respectively). MMP-3 significantly correlated with DAS28 (p= 0.0001) and vdHSS
(r= 0.78, p= 0.0001) and a significant difference was shown in those with erosions compared
to those without (p= 0.001). Serum MMP-3 levels significantly correlated negatively with cumula-
tive steroid dose (r= 0.2, p= 0.03) and were significantly higher in patients who never received
disease-modifying antirheumatic drugs (p= 0.001). There were no significant relations of MMP-3
with age, MHAQ, VAS for pain.t, Bani-
154 S. Fadda et al.Conclusion: These results indicate that serum MMP-3 is a measurable, useful specific marker of
disease activity and joint damage in RA patients.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid Arthritis (RA) is a systemic inflammatory disease
of unknown etiology characterized by destructive joint disease,
impaired function, progressive disability and increased mortal-
ity [1]. Synovial inflammation underlies the cardinal manifesta-
tions of this disease, which include pain, swelling, and
tenderness followed by cartilage destruction, bone erosion,
and subsequent joint deformities [2]. In RA, joint involvement
is typically symmetric, a character usually not found in other
forms of arthritis [3]. In Egyptian RA patients cytokines [4],
oxidative stress [5,6] and biomarkers of apoptosis [7] were
found to play a key role in the pathogenesis of RA with a
prominent relation to disease activity. In another study, syn-
ovitis and tenosynovitis detected by ultrasound in Egyptian
RA patients showed a significant relation with the erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), rheuma-
toid factor, disease activity and functional impairment [8].
Indeed, the rate of cartilage and joint damage is correlated
with plasma elevations in inflammatory acute phase reactants,
such as CRP and ESR, rheumatoid factor positivity, and the
synovial concentrations of matrix metalloproteinase (MMP),
a matrix digesting enzymes directly responsible for joint
destruction [9].
The MMPs are thought to play a critical role in the degra-
dation of many components of the extracellular matrix in the
synovial joint [10]. Matrix metalloproteinase-3 (stromelysin-
1) is a proteolytic enzyme which is thought to play a pivotal
role in joint destruction in RA through breaking down various
extracellular components, including collagens (types III, IV, V,
IX, and XI), matrix proteins and proteoglycans and activating
other pro-MMPs such as pro-MMP-7, pro-MMP-8 and pro-
MMP-9 [11]. The serum level of MMP-3 was increased in
Egyptian patients with other rheumatic as it was associated
with arthritis in systemic lupus erythematosus patients and
considered a potential biomarker of disease activity and dam-
age [12], related to disease activity in ankylosing spondylitis
[13] and was significantly higher in polyarticular juvenile idio-
pathic arthritis [14].
In RA, MMP-3 is locally produced in the inflamed joint,
and released into the blood stream [15]. It has been suggested
that serum MMP-3 levels correlate with levels produced by the
synovium, and thus reflect the level of activity of rheumatoid
synovitis [11,16]. MMP-3 plays a pivotal role in the destruction
of bone and degradation of cartilage components in RA and
the baseline levels were significantly higher in those with
high-progression making it a strong prognostic marker of dis-
ease activity and an early predictor of progressive joint damage
in recent-onset Egyptian RA patients [17]. Another study dis-
played a significantly elevated MMP-3 level in the serum and
synovial fluid of RA patients compared to patients with
osteoarthritis [18].
The aim of the present study is to assess the serum level of
MMP-3 in rheumatoid arthritis patients, and to evaluate itssignificance as a marker of functional disability, disease activ-
ity and joint destruction.
2. Patients and methods
Fifty adult RA patients (44 females and 6 males) as defined by
the 2010 ACR/EULAR classification criteria [19] formed the
basis of this study and were collected from the outpatient clinic
of the Rheumatology and Rehabilitation department, Bani-
Suef University Hospital. Twenty healthy adults (12 females
and 8 males) served as a control group. The study was
approved by the local ethical committee in accordance with
the declaration of Helsinki ethical standards. Informed con-
sent was obtained from all patients and controls for inclusion
in the study.
2.1. Clinical assessment
Demographic data and disease history taking regarding onset,
duration, course, progression and associated diseases were
obtained from all patients. Number of painful and swollen
joints (28 joints) and visual analogue scale (VAS) of pain (ran-
ged from 0-10; 0 means there is no pain, 10 means that it is the
worst possible pain patient had felt) were evaluated and dis-
ability was assessed according to the Modified Health Assess-
ment Questionnaire (MHAQ) [20]. Disease activity was
assessed with disease activity score in 28 joints (DAS28) [21].
2.2. Laboratory assessment
The following was done for all patients and controls: Complete
blood count (CBC), ESR by Westergren method, CRP, urine
analysis, full blood chemistry, including renal and liver
function tests. Rheumatoid factor (RF IgM, U/L) was
measured for all patients by agglutination slide for qualita-
tive determination and serum anti-cyclic citrullinated peptide
(anti-CCP) antibodies were measured. Test for Matrix
Metalloproteinase-3 (MMP-3) using ELISA technique (R&D
Systems, Catalog #DMP 300) was done for all patients and
control.
2.3. Preparation of samples
Five ml of blood were withdrawn from each patient and the
serum was separated by centrifugation; then sera were labeled
and stored at 20 C until used.
2.4. MMP-3 assay procedure
Add 100 lL standard or sample was added to each well and
incubated 2 hours at 37 C. 100 lL Detection Reagent A was
aspirated, added and incubated 1 hour at 37 C then washed
3 times. 100 lL Detection Reagent B was added and incubated
Table 1 Demographic, clinical and laboratory characteristics
of RA patients.
Characteristic mean ± SD
(range) or n (%)
RA patients (n= 50)
Age (years) 46.4 ± 13.6 (20–70)
Age of onset (years) 40.9 ± 12.6 (19–64)
Disease duration (years) 5.6 ± 4.8 (1–15)
Sex
Female 44 (88)
Male 6 (12)
Disease duration groups
Group 1 (1–5 years) 27 (54)
Group 2 (5–10 years) 12 (24)
Group 3 (>10 years) 11 (22)
DAS28 5.2 ± 2 (2.6–8.6)
MHAQ 1.5 ± 0.6 (0.5–2.8)
VAS 53.3 ± 22.96 (20–95)
ESR (mm/1st hr) 56.04 ± 29.8 (15–120)
CRP (mg/L) 25.5 ± 28.1 (3–96)
TLC (cells/mm3) 7.2 ± 2.9 (3.9–13.6)
Hb (gm/dl) 11.6 ± 1.7 (7.8–15)
Pl (103/mm3) 350 ± 96 (190–447)
AST (mg/dl) 24.1 ± 9.5 (12–50)
ALT (mg/dl) 24.3 ± 19.1 (7–55)
Serum creatinine (mg/dl) 0.53 ± 0.11 (0.4–0.8)
DAS28: 28 joint disease activity score, MHAQ: modified health
assessment questionnaire, VAS: visual analogue scale of pain, ESR:
erythrocyte sedimentation rate, CRP: C-reactive protein, TLC:
total leukocytic count; Hb: hemoglobin, Pl: platelets.
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Solution was added and incubated 30 minutes at 37 C.
50 lL Stop Solution was added and immediately read at
450 nm. A standard curve was created by blotting absorbance
of each standard concentration against MMP-3 concentration.
For each sample concentration was obtained from standard
curve, then multiplied by 10 (dilution factor).
2.5. Radiological assessment
In all patients, plain radiographs of both hands and feet in the
postro-anterior projections were obtained. Van der Heijde-
modified Sharp Score (vdHSS) was used to assess radiological
changes [22].
2.6. Statistical methods
Statistical package for social science (SPSS) software version
17 was used. Descriptive analysis of the results in the form
of percentage distribution for qualitative data and minimum,
maximum, mean and standard deviation calculation for quan-
titative data was done. Cross tabulation test was performed for
comparison between percentage values, Student t-test for com-
parison between means of two groups and F-Test (One way
ANOVA) for comparison between means of three groups.
Pearson’s correlation was done to describe the relationship
between two variables. In all tests: p< 0.05 was significant.
3. Results
The study included 50 adult RA patients (6 males and 44
females); their age ranged from 20 to 70 years with a mean
of 46.36 ± 13.63 years and their disease duration ranged from
1 to 15 years with a mean of 5.6 ± 4.75 years. The patients
were classified into three groups according to the disease dura-
tion. The demographic and clinical characteristics as well as
the DAS28, MHAQ, VAS for pain, ESR and CRP of the
patients are shown in Table 1. 20 healthy controls included 8
males (40%) and 12 females (60%) with a mean age of 50.5
± 9.6 years. The controls were age (p= 0.17) and sex
(p= 0.55) matched with the patients.
Rheumatoid factor was positive in 38 patients (76%) and
negative in 12 patients (24%); while Anti-CCP was positive
in 42 patients (84%), and negative in 8 patients (16%). Radi-
ological score (vdHSS) ranged between 3 and 420 with a mean
of 95.36 ± 111.41.
There were 30 RA patients using methotrexate (60%) with
a dose ranging from 12.5-25 mg/week with a mean of 17.5
+ 3.25 mg/week, 15 patients were using leflunomide (30%),
22 patients were using antimalarial (38%), and 36 patients
were using steroids (72%) with a dose ranging from 2.5 to
15 mg/day with a mean of 8.63 + 2.35 mg/day with total
cumulative dose (20.65 ± 10.97 g). Some patients were under
more than one line of treatment at the same time.
Testing the level of serum MMP-3 in RA patients, it ranged
from 5.3 to 162.8 ng/ml with a mean of 46.78 ± 46.99 ng/ml.
On the other hand, the levels of MMP-3 in the sera of normal
controls ranged from 0.16 to 6.88 ng/ml with a mean of 1.98
± 1.71 ng/ml. The mean serum level of MMP-3 in RA patients
was significantly higher than those in healthy controls
(p= 0.0001) (Fig. 1).There was an insignificant correlation between serum
MMP-3 levels and the age of the patients (r= 0.22,
p= 0.12). There was no significant difference between mean
MMP-3 levels in male patients compared to females
(p= 0.24). On comparing the serum levels of MMP-3 among
different disease duration groups of RA patient; it was statis-
tically significant (r= 0.32, p= 0.03); with the highest mean
levels found in patients with disease duration >10 years
(Group 3).
Serum MMP-3 levels significantly correlated with DAS28
score (r= 0.57, p= 0.0001). The mean values of MMP-3 were
higher in patients with highly active disease than those with
moderate or low disease activity score (Fig. 2). MMP-3
insignificantly correlated with the VAS for pain (r= 0.15)
and MHAQ (r= 0.24).
Comparison of MMP-3 serum levels between CRP, RF and
anti-CCP positive and negative groups showed a significant
difference (p= 0.0001; p= 0.009 and p= 0.042 respectively)
(Table 2). The serum level of MMP-3 showed a significant cor-
relation with the ESR (r= 0.62, p= 0.001) (Fig. 3a).
Serum MMP-3 significantly correlated with the vdHSS,
(r= 0.78, p< 0.0001) in RA patients (Fig. 3b); the difference
was significant in those with erosions compared to those with-
out (p= 0.001) (Fig. 4).
Serum MMP-3 levels significantly negatively correlated
with total cumulative steroid dose in the RA patients
(r= 0.2, p= 0.03) and when compared between patients
receiving and those who never received steroids, there was a
highly significant difference (p= 0.004). There was a highly
significant difference between MMP-3 serum levels in RA
Figure 1 Serum MMP-3 level in rheumatoid arthritis patients
and controls.
Figure 2 Serum MMP-3 levels in relation to DAS 28 score in
rheumatoid arthritis patients.
Table 2 Comparison of serumMMP-3 between CRP, RF and
Anti-CCP positive and negative groups.
MMP-3 (ng/ml) in RA patients
Mean ± SD p
CRP Negative 12.19 ± 5.67 0.0001
Positive 64.6 ± 49
RF Negative 27.72 ± 41.8 0.009
Positive 52.8 ± 47.42
Anti-CCP Negative 16.01 ± 9.15 0.042
Positive 52.64 ± 49.03
CRP, C-reactive protein; RF, Rheumatoid factor; Anti-CCP, anti-
cyclic citrullinated peptide. Bold values are significant at p< 0.05.
156 S. Fadda et al.patients who never received DMARDs (63.71 ± 49 ng/ml)
and those receiving (11.183 ± 5.66 ng/ml) (p= 0.001).
4. Discussion
Some baseline demographic and laboratory markers in RA
(e.g. female sex, older age, RF, anti-CCP seropositivity, raised
CRP or ESR) have been associated with a poor prognosis. Sur-
prisingly, none of these markers specifically reflect ongoing
destructive processes within bone and synovium [23]. The
increased MMP-3 serum level is associated with the presence
of synovitis, reflecting the inflammatory reaction occurring in
the joints, whether acute or chronic, of erosive potential or
not and positively correlated with the number of joints affected
[24].
In the present study, serum MMP-3 levels were significantly
higher in the RA patients than in controls (p= 0.0001). This
nearly coincides with the results of Ally et al. [1] and Tchetver-
ikov et al. [25]. There was no significant difference in the level
between male and female patients (p= 0.24). In agreement
was the study of Sun et al. [26] that reported no sex differences
in MMP-3 levels in their RA patients. In contrast to our
results, Ribbens et al. [24] reported that serum levels of
MMP-3 were significantly higher in men than in women
(p< 0.0001).
On correlating serum MMP-3 levels with the age of our
patients we had found no significant correlation (p= 0.12)
and this agrees with the results of Keyszer et al. [27], since
the influence of inflammatory processes on MMP-3 levels,
probably outweighs the effect of age. There was a significant
correlation between serum MMP-3 levels and disease durationwith the highest levels in patients with disease duration
>10 years. This may be due to the destructive progression
which is thought to be mediated by potent enzymes which
breakdown the tissues of the joint. The MMP family is heavily
implicated in these processes, as collectively they are able to
degrade most components of cartilage [28].
MMP-3 significantly correlated with disease activity as
measured by DAS28, being higher in the patients with high
disease activity than those with moderate or low disease activ-
ity. However, no significant correlation was found between
MMP-3 and VAS for pain or MHAQ. On the contrary, it
has been postulated that an over-expression of MMP-3 in syn-
ovial fluid, rheumatoid synovium and cartilage as well as an
increased level of MMP-3 in the serum obtained from RA
patients clearly reflects its contribution in chronic inflamma-
tion and joint destruction [29]. This comes in agreement with
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Figure 3 Correlation between serum levels of MMP-3 and (a)
ESR (b) modified Sharp Score in RA patients.
Figure 4 Serum MMP-3 levels in rheumatoid arthritis patients
with and without erosions according to the Van der Heijde-
modified Sharp Score (vdHSS).
Serum matrix metalloproteinase-3 and rheumatoid arthritis 157the findings of Ates et al. [30]; Serum pro-MMP-3 levels were
found to be significantly higher their patients having high
(54.6 ng/ml) or moderate disease activity (46.2 ng/ml) thanthose with low disease activity (27.3 ng/ml) (p< 0.01); while
there were no significant differences of the VAS (r= 0.13,
p> 0.05). In contrast, the correlation of MMP-3 with the
health assessment questionnaire (HAQ) investigated by Green
et al. [31], found a significant correlation (r= 0.23, p< 0.01)
in early untreated RA patients and concluded that baseline
serum MMP-3 levels predict functional outcome.
In our work, on correlating MMP-3 serum levels, with
some established laboratory markers of RA as ESR, CRP,
RF and anti-CCP we found that, serum MMP-3 levels signif-
icantly correlated with ESR (p= 0.001), with significant dif-
ferences between positive and negative CRP, RF and Anti-
CCP patients (p= 0.0001, p= 0.009, p= 0.042, respectively).
In support to our results Ally et al. [1]; found that MMP-3 cor-
related significantly with laboratory measures, specifically
ESR, CRP, and RF but there was no significant association
of MMP-3 with anti-CCP. Another study [26] also found that
MMP-3 levels correlated with markers of inflammation (ESR
and CRP) and Visvanathan et al. [32] showed significant cor-
relations with CRP (r= 0.6, p< 0.001). Confirming our
results, the study of Peake et al. [33] found that MMP-3 levels
correlated significantly with ESR (r= 0.41, p= 0.01). In a
study on Egyptian RA patients, MMP-3 strongly correlated
with the CRP [18].
In our study, according to the Van der Heijde-modified
Sharp Score (vdHSS), serum MMP-3 levels were significantly
higher in erosive RA patients than non-erosive (p= 0.001).
Our results agreed with Tchetverikov et al. [34], who had
examined 109 patients with RA of recent onset, and had fol-
lowed the patients for 2 years. They had found that MMP-3
levels were significantly higher in the group of severe joint
damage progression compared with mild disease at all times,
at baseline, at 1 and 2 years (p= 0.02, p= 0.001 and
p= 0.004 respectively). Houseman et al. [23] demonstrated
that the measurement of serum MMP-3 levels at baseline adds
to the predictive value of anti-CCP in determining the long-
term radiographic outcome in patients with RA. Young-Min
et al. [35] had stated that serum levels of MMP-3 predicted
and correlated with radiographic progression and joint
destruction. These results supported the notion that MMP-3
has a significant role in the pathogenesis of RA. The relation-
ship between MMP-3 serum levels and the progression of joint
damage in early RA, was also studied by Cunnane et al. [36]
who had noted that serum MMP-3 were higher in RA versus
non-RA patients (seronegative spondylarthropathy, undiffer-
entiated arthritis, and self-limiting arthritis) and that the num-
ber of joint erosions at presentation significantly correlated
with baseline MMP-3 (p= 0.003). Moreover, in a 1-year fol-
low up study on Egyptian RA patients there was a significant
correlation between baseline levels of MMP-3 and MRI ero-
sion score while after 1-year there was a significant correlation
with the van der Heijde modification of the Sharp scoring sys-
tem score [17].
The serum MMP-3 levels were significantly higher in
patients receiving and those who never received steroids
(p= 0.004); Serum MMP-3 levels negatively correlated with
cumulative steroid therapy in our RA patients (r= 0.2,
p= 0.03) and this is matched with results of Ribbens et al.
[24] and Green et al. [31]. There was a highly significant differ-
ence between MMP-3 serum levels in RA patients who never
received and those receiving different conventional DMARDs
(p= 0.001). In agreement to our findings; serum MMP-3
158 S. Fadda et al.levels in patients treated with MTX are consistent with Catrina
et al. [37] that have shown a decrease in circulating MMP-3
levels with conventional and biological DMARDs therapy.
Supporting evidence for the prognostic significance of MMP-
3 in RA, however, includes its expression in RA synovial tissue
and the decreasing serum MMP-3 levels following DMARD
treatment [38].
In conclusion, elevated MMP-3 serum levels reflect disease
activity in RA patients and can be used as a specific marker for
joint damage but the cross sectional design of this study did
not allow us to produce conclusions with respect to disease
course and prognosis. Thus we recommend further studies
on large numbers of patients and serial measurements of
MMP-3 to determine the rate of disease progression or erosion
development and we recommend using MMP-3 level as a use-
ful marker for disease activity.
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